EP1001805A1 - Procedes d'identification d'anticorps et de peptides utiles dans le traitement du choc septique et de l'arthrite experimentale; utilisation de ces derniers - Google Patents

Procedes d'identification d'anticorps et de peptides utiles dans le traitement du choc septique et de l'arthrite experimentale; utilisation de ces derniers

Info

Publication number
EP1001805A1
EP1001805A1 EP98930343A EP98930343A EP1001805A1 EP 1001805 A1 EP1001805 A1 EP 1001805A1 EP 98930343 A EP98930343 A EP 98930343A EP 98930343 A EP98930343 A EP 98930343A EP 1001805 A1 EP1001805 A1 EP 1001805A1
Authority
EP
European Patent Office
Prior art keywords
mucopeptide
peptide
die
group
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98930343A
Other languages
German (de)
English (en)
Inventor
John B. Zabriskie
Milan S. Blake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of EP1001805A1 publication Critical patent/EP1001805A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria

Definitions

  • the present invention relates to methods for identifying new peptides useful in the treatment of septic shock, experimental arthritis and related maladies. These new peptides are selected, in part, for their affinity to or mimicry of anti-Group A mucopeptide antibodies. The therapeutic use of the new peptides and the related antibodies in the treatment of septic shock are disclosed.
  • the basic repeating unit is an alternating motif of Neuraminic Acid-N- acetyl glucosamine (NAM-NAG) molecules in which the inter-peptide bridges vary from organism to organism.
  • NAM-NAG Neuraminic Acid-N- acetyl glucosamine
  • the gram negative bacteria share a common glycolipid commonly known as lipid A, to which various oligo- and polysaccharides are added depending on the bacteria.
  • lipid A The common structure of lipid A is shown in Figure 2. It is well known that both Lipid A and the mucopeptide complex will individually elicit an extremely vigorous toxic response when injected into animals. The most serious of these responses is the oftentimes massive production of tumor necrosis factor (TNF ⁇ ).
  • TNF ⁇ tumor necrosis factor
  • the present invention teaches the use of antibodies raised against the Group A mucopeptide for the treatment of inflammatory diseases such as septic shock and rheumatoid arthritis, Crohn's disease, psoriasis, and for the identification of specific peptides that can be used in such treatments.
  • the specific peptides will serve as mimics to these antibodies.
  • the peptides will serve as binding partners for these antibodies.
  • One aspect of the present invention is derived from the premise that there exists a common structural motif for gram positive and gram negative bacteria. The present invention exploits the ramifications of this premise and thereby introduces novel approaches of identifying treatments for septic shock and related diseases.
  • One feature of the present invention is the generation and identification of antibodies that bind to a common motif present on both Lipid A and the Group A mucopeptide.
  • a related aspect of the present invention is the generation and characterization of peptides that mimic these antibodies.
  • the peptides act by associating with LPS and the Group A mucopeptide, and thus inhibit these bacterial agents from binding to their receptor(s). This, in turn, can prevent the induction of TNF ⁇ and the onset of septic shock.
  • the present invention includes methods of obtaining such inhibitory peptides.
  • the inhibitory peptides are obtained by contacting a phage library with permissive bacteria.
  • the phage library contains an assortment of phage with each individual phage comprising a random DNA sequence that encodes specific peptides.
  • the DNA sequences of the phage library are expressed and a variety of random peptides are generated.
  • the random peptides are contacted with the mucopeptide complex, and candidate peptides are selected on the basis of their ability to bind the mucopeptide complex. Phage containing the candidate peptides are purified and DNA that encode the candidate peptides are sequenced. The amino acid sequence for the candidate peptide can then be deduced.
  • the candidate peptides are synthesized per their respective amino acid sequences.
  • the synthesis can be performed, for example, by standard genetic engineering techniques or more preferably by solid phase peptide synthesis.
  • the synthetic candidate peptides are then contacted with Lipid A, and further characterized by their ability to bind Lipid A. In this manner peptides that bind both Lipid A and the Group A mucopeptide can be obtained.
  • the selected peptides are further contacted with the Group A mucopeptide and an anti- Group A mucopeptide antibody.
  • Inhibitory peptides are chosen from selected peptides on the basis of their distinctive ability to inhibit the formation of that antigen-antibody complex.
  • an inhibitory peptide is further selected on the basis of its ability to inhibit the bacterial-mediated production of tumor necrosis factor (TNF ⁇ ).
  • This method includes the additional step of contacting an inhibitory peptide with a mononuclear cell that is challenged with either LPS or the mucopeptide.
  • the inhibitory peptide binds to a common structural element present in both the Group A mucopeptide and the LPS molecule.
  • inhibitory peptides obtained by the methods described herein are also part of the present invention. These inhibitory peptides have the following characteristics: they bind to both the Group A mucopeptide and the LPS molecule; and in addition, inhibit the association between an anti-Group A mucopeptide antibody and its Group A mucopeptide antigen.
  • the inhibitory peptide further inhibits the bacterial-mediated production of tumor necrosis factor in a target cell.
  • the target cell can be a mononuclear cell or any other cell which secretes cytokines in response to stimulation by the Group A mucopeptide and/or the LPS molecule.
  • the mononuclear cell is human.
  • the present invention also includes pharmaceutical compositions for treating septic shock, rheumatoid arthritis, Crohn's disease, psoriasis and experimental arthritis comprising an inhibitory peptide of the present invention and a pharmaceutically acceptable carrier.
  • Methods of treating septic shock in mammals which comprise administering to the mammal a therapeutically effective amount of such pharmaceutical compositions, are included in the present invention.
  • the mammal is a human.
  • the present invention also includes methods of treating experimental arthritis comprised of administering to the subject animal a therapeutically effective amount of a pharmaceutical composition comprising an inhibitory peptide of the present invention and a pharmaceutically acceptable carrier.
  • Analogous methods of treating rheumatoid arthritis by administering to a human a therapeutically effective amount of the pharmaceutical compositions comprising an inhibitory peptide of the present invention and a pharmaceutically acceptable carrier are contemplated by the present invention.
  • a related aspect of the invention is a method of blocking the LPS-mediated induction of TNF ⁇ in a mononuclear cell, by adding an antibody prepared against pure Group A mucopeptide to the mononuclear cell.
  • the mononuclear cell is human.
  • Another aspect of the present invention is derived on the premise that the mucopeptide complex elicits an immune response that is comparable to rheumatoid arthritis.
  • This aspect of the invention includes methods of identifying an antigenic peptide.
  • One specific embodiment of such a method comprises the steps of administering to an animal a selected peptide, then administering to the animal an amount of Group A mucopeptide capable of inducing experimental arthritis in said animal, and finally, identifying an antigenic peptide on the basis of the ability of the selected peptide to elicit a protective antibody response against the Group A mucopeptide induced experimental arthritis in the animal.
  • the animal is a rat and the amount of Group A mucopeptide administered is in a dose equivalent to the Group A cell fragments containing 15-30 ⁇ g of rhamnose per gram of body weight of the rat, i.e. , a dose equivalent to 3-6 mgs of rhamnose for a 200 gram rat.
  • the amount of mucopeptide is typically expressed as a function of the quantity of rhamnose determined on the mucopeptide, because the rhamnose content of the mucopeptide is relatively constant and readily determined].
  • 125 ⁇ gs to 250 ⁇ gs of the selected peptide per gram of body weight of the rat i.e.
  • a dose of 25 to 50 mgs of the selected peptide for a 200 gram rat is administered to the animal prior to the administration of the Group A mucopeptide.
  • the selected peptide may be selected on the basis of its ability to bind to an anti-Group A mucopeptide antibody and inhibit its binding to the Group A mucopeptide.
  • One related method for selecting such a peptide comprises contacting an assortment of random peptides with an anti-Group A mucopeptide antibody, and choosing a candidate peptide on the basis of the ability of the candidate peptide to bind the Group A mucopeptide antibody; contacting the candidate peptide with the Group A mucopeptide, and choosing the selected peptide on the basis of the ability of the candidate peptide not to bind the Group A mucopeptide.
  • the selected peptide may then be recovered and/or otherwise identified and used in the screening assay described above for identifying an antigenic peptide of the present invention.
  • the assortment of random peptides may be obtained from a phage library.
  • the selected peptides are obtained by contacting a phage library with permissive bacteria.
  • the phage library contains an assortment of phage with each individual phage comprising a random DNA sequence that encodes specific peptides.
  • the DNA sequences of the phage library are expressed and a variety of random peptides are generated.
  • the selected peptide may be recovered as follows: the phage encoding the selected peptide can be purified and the DNA that encodes the selected peptide can be sequenced. The amino acid sequence for the selected peptide can then be deduced from the DNA sequence.
  • synthetic combinatorial libraries can be used.
  • the selected peptides can then be synthesized per their respective amino acid sequences.
  • the synthesis can be performed, for example, by standard genetic engineering techniques or more preferably by solid phase peptide synthesis.
  • the antigenic peptides obtained by the methods described herein are also part of the present invention. These inhibitory peptides have the following characteristics: they do not bind to the Group A mucopeptide; they do bind to an anti-Group A mucopeptide antibody; and they elicit a protective antibody response in animals against Group A mucopeptide induced experimental arthritis.
  • the present invention also includes pharmaceutical compositions comprising an antigenic peptide of the present invention and a pharmaceutically acceptable carrier.
  • the present invention also includes methods of analyzing the ability to prevent the onset of experimental arthritis in an animal induced to develop experimental arthritis. In one embodiment the method comprises administering to the animal an antibody prepared against the Group A mucopeptide prior to the onset of experimental arthritis, thereby preventing the onset of experimental arthritis. In another embodiment a method for preventing the onset of experimental arthritis comprises administering to the animal a pharmaceutical composition comprising an antigenic peptide of the present invention and a pharmaceutically acceptable carrier prior to the onset of experimental arthritis.
  • the present invention also includes methods of treating experimental arthritis in an animal.
  • the method comprises administering to the animal an antibody prepared against the Group A mucopeptide after the onset of experimental arthritis, whereby the experimental arthritis in said animal is ameliorated.
  • the present invention includes a method of administering to the animal the pharmaceutical composition comprising an antigenic peptide of the present invention and a pharmaceutically acceptable carrier after the onset of experimental arthritis, whereby the experimental arthritis in said animal is ameliorated.
  • FIGURE 1 PRIOR ART. The structure of the mucopeptide complex of the gram- positive bacterial cell wall. Depiction of a schematic drawing of the polysaccharide- peptide complex (mucopeptide complex) of the cell wall of gram positive bacteria.
  • FIGURE 2 PRIOR ART. The structure of the glycolipid complex of the gram- negative bacterial cell wall. Depiction of a schematic drawing of the glycolipid (Lipid A) of the cell wall of gram negative bacteria.
  • FIGURE 3 Comparison of the structures of the mucopeptide and the glycolipid complex. Depiction of the comparison of the structures of the peptidoglycan (mucopeptide complex) and Lipid A.
  • FIGURE 4 TNF ⁇ induction by bacterial cell wall components in the presence and absence of antibodies prepared against the pure group A streptococcal mucopeptide.
  • the present invention discloses novel methods and compositions for treating septic shock, Crohn's disease, psoriasis, and rheumatoid arthritis through the use of antibodies raised against the Group A mucopeptide. These antibodies may be used directly, or indirectly by identifying specific peptides that can be used in such treatments.
  • the present invention includes the use of antibodies prepared against the pure Group A streptococcal mucopeptide that are able to block the induction of TNF alpha in human mononuclear cells regardless of whether they were stimulated by either Group A mucopeptide obtained from gram positive bacteria or LPS obtained from gram negative organisms (see Figure 4).
  • the present invention describes a novel approach of using anti-mucopeptide antibodies to help identify novel peptides which will bind to the common structural element present on the Group A mucopeptide and on the LPS molecule. These peptides resemble the binding domains within the anti-mucopeptide antibodies and thus can block the binding of the cell receptor to the common structural element present in Group A mucopeptide and LPS. This, in turn, inhibits the induction of TNF alpha by the target cell. Accordingly, the present invention includes the investigation of diseases, such as septic shock, Crohn's disease, psoriasis and experimental arthritis (an animal model for Rheumatoid Arthritis) using this novel approach. It would be understood by any person with skill in the relevant art that such diseases are only meant to be exemplary and other diseases having related mechanisms can also be successfully treated by the teachings herein.
  • diseases such as septic shock, Crohn's disease, psoriasis and experimental arthritis (an animal model for Rheumato
  • mucopeptide complex As used herein, the terms “mucopeptide complex”, “Group A mucopeptide”, “peptidoglycan”, and the “polysaccharide-peptide complex” are used interchangeably and denote an integral aspect of the cell wall of gram positive bacteria. Pieces of this integral aspect induce an immunological response in mammals that can include septic shock.
  • Lipid A As used herein, the terms "Lipid A”, “glycolipid”, “lipopolysaccharides” or “LPS” are used interchangeably and denote an integral aspect of the cell wall of gram negative bacteria. Pieces of this integral aspect induce an immunological response in mammals that can include septic shock.
  • an "inhibitory peptide” has the following characteristics: it binds the Group A mucopeptide; it binds the LPS molecule; and it inhibits an anti-Group A mucopeptide antibody from binding the Group A mucopeptide.
  • an "antigenic peptide” has the following characteristics: it does not bind to the Group A mucopeptide; but it does bind to an anti-Group A mucopeptide antibody; and it elicits a protective antibody response in animals against Group A mucopeptide induced experimental arthritis.
  • a "common structural element” is used interchangeably with a “common structural motif” and denotes a three dimensional structural similarity which allows at least one binding partner to selectively bind to at least two otherwise distinctive molecules that contain such a common structural motif with a comparable affinity.
  • experimental arthritis has clinical symptoms including redness and swelling of the paws of the animal. Such symptoms can be monitored by observation and/or by measurement of paw diameter. These symptoms wax and wane over time. An increased paw size is indicative of arthritis.
  • mucopeptide prepared from natural sources, or produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins may be used as an immunogen to generate antibodies that recognize the mucopeptide and LPS.
  • LPS prepared from natural sources, or by chemical synthesis, and fragments or other derivatives or analogs thereof may be used as an immunogen to generate antibodies that recognize both the mucopeptide and LPS.
  • Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.
  • a molecule is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor.
  • An antigenic polypeptide contains at least about 5, and preferably at least about 10, amino acids.
  • An antigenic portion of a molecule can be that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization.
  • a molecule that is antigenic need not be itself immunogenic, i.e. , capable of eliciting an immune response without a carrier.
  • an “antibody” is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope.
  • the term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567, as well as antigen binding portions of antibodies, including Fab, F(ab') 2 and F(v) (including single chain antibodies).
  • the phrase "antibody molecule” in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule containing the antibody combining site.
  • An “antibody combining site” is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.
  • Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab' , F(ab') 2 and F(v), which portions are preferred for use in the therapeutic methods described herein.
  • Fab and F(ab') 2 portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous et al. Fab' antibody molecule portions are also well-known and are produced from F(ab') 2 portions followed by reduction of the disulfide bonds linking die two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide.
  • An antibody containing intact antibody molecules is preferred herein.
  • the phrase "monoclonal antibody” in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen.
  • a monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts.
  • a monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) monoclonal antibody.
  • adjuvant refers to a compound or mixture that enhances the immune response to an antigen.
  • An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response [Hood et al, in Immunology, p. 384, Second Ed., Benjamin/Cummings, Menlo Park, California (1984)].
  • a primary challenge with an antigen alone, in the absence of an adjuvant will fail to elicit a humoral or cellular immune response.
  • Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Gueri ⁇ ) and Corynebacterium parvum.
  • the adjuvant is pharmaceutically acceptable.
  • the mucopeptide and LPS can be immunized by injection with the mucopeptide or LPS, or a derivative (e.g. , fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc.
  • the mucopeptide, LPS or fragment thereof can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH).
  • BSA bovine serum albumin
  • KLH keyhole limpet hemocyanin
  • adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette- Gueriri) and Corynebacterium parvum.
  • BCG Bacille Calmette- Gueriri
  • Corynebacterium parvum bacille Calmette- Gueriri
  • any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler et al, Nature, 256:495-497 (1975), as well as the trioma technique, the human B-cell hybridoma technique [Kozbor et al, Immunology Today, 4:72 (1983)], and the EBV-hybridoma technique to produce human monoclonal antibodies [Cole et al, in Monoclonal Antibodies and Cancer Therapy, pp. 77-96, Alan R. Liss, Inc., (1985)].
  • Immortal, antibody-producing cell lines can be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al, "Hybridoma Techniques” (1980); Hammerling et al, “Monoclonal Antibodies And T-cell Hybridomas” (1981); Kennett et al, “Monoclonal Antibodies” (1980); see also U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; and 4,493,890.
  • monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545).
  • human antibodies may be used and can be obtained by using human hybridomas [Cote et al, Proc. Natl. Acad. Sci. USA, 80:2026-2030 (1983)] or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, supra).
  • techniques developed for the production of "chimeric antibodies” [Morrison et al, J. Bacteriol, 159-870 (1984); Neuberger et al, Nature, 312:604-608 (1984); Takeda et al.
  • human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described infra), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.
  • Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques.
  • such fragments include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
  • screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc.
  • radioimmunoassay e.g., ELISA (enzyme-linked immunosorbent assay), "sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoa
  • antibody binding is detected by detecting a label on the primary antibody.
  • the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody.
  • the secondary antibody is labeled.
  • Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope common to the mucopeptide and LPS, one may assay generated hybridomas for a product which binds to a mucopeptide or LPS fragment containing such an epitope.
  • the foregoing antibodies can be used in methods known in the art relating to the localization and activity of the mucopeptide or LPS e.g., for Western blotting, imaging the mucopeptide or LPS in situ, measuring levels thereof in appropriate physiological samples, etc.
  • antibodies that agonize or antagonize the activity of the mucopeptide and LPS can be generated. Such antibodies can be tested using the assays described infra for identifying ligands.
  • antibodies are developed by immunizing rabbits with synthetic peptides predicted by the sequence of the mucopeptide.
  • Synthetic peptides may be conjugated to a carrier such as KLH hemocyanin or BSA using carbodumide and used in Freund's adjuvant to immunize rabbits.
  • the expressed peptide may be prepared in quantity and used to immunize rabbits in Freund's adjuvant.
  • the mucopeptide is used to immunize chickens, and the chicken anti-mucopeptide antibodies are recovered from egg yolk, e.g., by affinity purification on a mucopeptide-column.
  • the affinity purified antibodies can be selected by subsequent purification on a LPS-column.
  • chickens used in immunization are kept under specific pathogen free (SPF) conditions.
  • SPF pathogen free
  • the mucopeptide is used to immunize rabbits, and the polyclonal antibodies are immunopurified on a mucopeptide-column and a LPS-column prior to further use.
  • the purified antibodies are particularly useful for semi-quantitative assays. Panels of monoclonal antibodies produced against me mucopeptide or LPS can be screened for various properties; i.e., isotype, epitope, affinity, etc. Of particular interest are monoclonal antibodies that neutralize the activity of the mucopeptide or LPS to bind to the TNF receptor. Such monoclonals can be readily identified in by the assays described herein. High affinity antibodies are particularly useful for this neutralization process.
  • the anti-modulator antibody used in the diagnostic and therapeutic methods of this invention is an affinity-purified polyclonal antibody. More preferably, the antibody is a monoclonal antibody (mAb).
  • mAb monoclonal antibody
  • the anti-mucopeptide or anti-LPS molecules used herein be in the form of Fab, Fab', F(ab') 2 or F(v) portions of whole antibody molecules.
  • amino acid refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
  • synthetic libraries [Needels et al., Proc. Natl. Acad. Sci. USA 90: 10700- 4 (1993); Ohlmeyer et al., Proc. Natl. Acad. Sci. USA 90:10922-10926 (1993); Lam et al., International Patent Publication No. WO 92/00252; Kocis et al., International Patent Publication No. WO 9428028, each of which is incorporated herein by reference in its entirety], and the like can be used to screen for the peptides of the present invention.
  • Synthetic peptides prepared using the well known techniques of solid phase, liquid phase, or peptide condensation techniques, or any combination thereof, can include natural and unnatural amino acids.
  • Amino acids used for peptide synthesis may be standard Boc (N ⁇ - amino protected N ⁇ -t-butyloxycarbonyl) amino acid resin with the standard de-protecting, neutralization, coupling and wash protocols of the original solid phase procedure of Merrifield (1963, J. Am. Chem. Soc. 85:2149-2154), or the base-labile N ⁇ -amino protected 9-fluorenylmethoxycarbonyl (Fmoc) amino acids first described by Carpino and Han (1972, J. Org. Chem. 37:3403-3409).
  • Both Fmoc and Boc N ⁇ -amino protected amino acids can be obtained from Fluka, Bachem, Advanced Chemtech, Sigma, Cambridge Research Biochemical, Bachem, or Peninsula Labs or other chemical companies familiar to those who practice this art.
  • the method of the invention can be used with other N ⁇ - protecting groups that are familiar to those skilled in this art.
  • Solid phase peptide synthesis may be accomplished by techniques familiar to those in the art and provided, for example, in Stewart and Young, 1984, Solid Phase Synthesis, Second Edition, Pierce Chemical Co., Rockford, IL; Fields and Noble, 1990, Int. J. Pept. Protein Res. 35:161-214, or using automated synthesizers, such as sold by ABS.
  • peptides of the invention may comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (e.g., ⁇ -methyl amino acids, C ⁇ -methyl amino acids, and N ⁇ -methyl amino acids, etc.) to convey special properties.
  • Synthetic amino acids include ornithine for lysine, fluorophenylalanine for phenylalanine, and norleucine for leucine or isoleucine. Additionally, by assigning specific amino acids at specific coupling steps, ⁇ -helices, ⁇ turns, ⁇ sheets, ⁇ -turns, and cyclic peptides can be generated.
  • the peptides may comprise a special amino acid at me C- terminus which incorporates either a C0 2 H or CONH 2 side chain to simulate a free glycine or a gly cine-amide group. Another way to consider this special residue would be as a D or L amino acid analog with a side chain consisting of the linker or bond to the bead.
  • the pseudo-free C-terminal residue may be of the D or the L optical configuration; in another embodiment, a racemic mixture of D and L-isomers may be used.
  • pyroglutamate may be included as the N-terminal residue of the peptide.
  • subunits of peptides that confer useful chemical and structural properties will be chosen.
  • peptides comprising D-amino acids will be resistant to L-amino acid-specific proteases in vivo.
  • the present invention envisions preparing peptides that have more well defined structural properties, and the use of peptidomimetics, and peptidomimetic bonds, such as ester bonds, to prepare peptides with novel properties.
  • a peptide may be generated that incorporates a reduced peptide bond, i.e., R,-CH 2 -NH-R 2 , where R, and R 2 are amino acid residues or sequences.
  • a reduced peptide bond may be introduced as a dipeptide subunit.
  • Such a molecule would be resistant to peptide bond hydrolysis, e.g., protease activity.
  • Such peptides would provide ligands witii unique function and activity, such as extended half-lives in vivo due to resistance to metabolic breakdown, or protease activity.
  • constrained peptides show enhanced functional activity (Hruby, 1982, Life Sciences 31:189-199; Hruby et al., 1990, Biochem J. 268:249-262); the present invention provides a method to produce a constrained peptide that incorporates random sequences at all other positions.
  • Constrained and cyclic peptides are prepared synthetically, provided that in at least two positions in the sequence of the peptide an amino acid or amino acid analog is inserted that provides a chemical functional group capable of crosslinking to constrain, cyclise or rigidize the peptide after treatment to form the cross-link. Cyclization will be favored when a turn-inducing amino acid is incorporated.
  • amino acids capable of crosslinking a peptide are cysteine to form disulfides, aspartic acid to form a lactone or a lactam, and a chelator such as ⁇ -carboxyl-glutamic acid (Gla) (Bachem) to chelate a transition metal and form a cross-link.
  • a chelator such as ⁇ -carboxyl-glutamic acid (Gla) (Bachem) to chelate a transition metal and form a cross-link.
  • Protected ⁇ -carboxyl glutamic acid may be prepared by modifying the synthesis described by Zee-Cheng and Olson (1980, Biophys. Biochem. Res. Commun. 94:1128-1132).
  • a peptide in which the peptide sequence comprises at least two amino acids capable of crosslinking may be treated, e.g.
  • non-classical amino acids may be incorporated in the peptide in order to introduce particular conformational motifs: l,2,3,4-tetrahydroisoquinoline-3-carboxylate (Kazmierski et al., 1991, J. Am. Chem. Soc.
  • LL-Acp LL-3-amino-2-propenidone-6- carboxylic acid
  • ⁇ -turn inducing dipeptide analog Kemp et al., 1985, J. Org. Chem. 50:5834-5838
  • ⁇ -sheet inducing analogs Kemp et al., 1988, Tetrahedron Lett. 29:5081- 5082
  • ⁇ -turn inducing analogs Kemp et al., 1988, Tetrahedron Lett.
  • the present invention further provides for modification or derivatization of a peptide of the invention.
  • Modifications of peptides are well known to one of ordinary skill, and include phosphorylation, carboxymethylation, and acylation. Modifications may be effected by chemical or enzymatic means.
  • glycosylated or fatty acylated peptide derivatives may be prepared. Preparation of glycosylated or fatty acylated peptides is well known in the art as exemplified by the following references:
  • Fatty acyl peptide derivatives may also be prepared.
  • a free amino group (N-terminal or lysyl) may be acylated, e.g. , myristoylated.
  • an amino acid comprising an aliphatic side chain of the structure - (CH 2 ) n CH 3 may be incorporated in the peptide.
  • sequence similarity in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that do not share a common evolutionary origin (see Reeck et al., supra).
  • sequence similarity when modified with an adverb such as “highly,” refers to sequence similarity and not a common evolutionary origin.
  • two DNA sequences are "substantially homologous” or “substantially similar” when at least about 50% (preferably at least about 75%, and most preferably at least about 90 or 95 %) of the nucleotides match over the defined length of the DNA sequences.
  • two amino acid sequences are "substantially homologous” or “substantially similar” when greater than 50% of the amino acids are identical, or greater than about 80% are similar (functionally identical).
  • the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin) pileup program.
  • corresponding to is used herein to refer similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured.
  • corresponding to refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases.
  • Identification of a specific DNA encoding a particularly long peptide of the present invention may be accomplished in a number of ways. For example, if an amount of a portion of the DNA or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to a labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). For example, a set of oligonucleotides corresponding to the amino acid sequence of the peptide can be prepared and used as probes for DNA. Those DNA fragments with substantial homology to the probe will hybridize. The greater the degree of homology, the more stringent hybridization conditions can be used.
  • a labeled probe Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A.
  • nucleotide sequence coding for a desired peptide, derivative or analog thereof, or a functionally active derivative can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted peptide-coding sequence. Such elements are termed herein a "promoter.”
  • a promoter a vector which contains the necessary elements for the transcription and translation of the inserted peptide-coding sequence.
  • An expression vector also preferably includes a replication origin.
  • the necessary transcriptional and translational signals can be provided on a recombinant expression vector.
  • Potential host-vector systems include but are not limited to mammalian cell systems infected with virus (e.g. , vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA.
  • the expression elements of vectors vary in tiieir strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.
  • Any of a number of metiiods for the insertion of DNA fragments into a such a vector may be used to construct expression vectors containing a nucleic acid consisting of appropriate transcriptional/translational control signals and the peptide coding sequences. These methods may include in vitro DNA and synthetic techniques.
  • Expression of peptide may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression.
  • Promoters which may be used to control the peptide nucleic acid expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A.
  • prokaryotic expression vectors such as the ⁇ -lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A.
  • Expression vectors containing a nucleic acid encoding an antigenic or inhibitory peptide of the invention can be identified by four general approaches: (a) PCR amplification of the desired plasmid DNA or specific mRNA, (b) nucleic acid hybridization, (c) presence or absence of selection marker gene functions, and (d) expression of inserted sequences.
  • the nucleic acids can be amplified by PCR to provide for detection of the amplified product.
  • the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted marker gene.
  • the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "selection marker" gene functions (e.g., ⁇ -galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector.
  • selection marker e.g., ⁇ -galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.
  • recombinants containing the peptide insert can be identified by the absence of the selection marker gene function.
  • recombinant expression vectors can be identified by assaying for the activity, biochemical, or immunological characteristics of the peptide expressed by the recombinant, by the methods described herein.
  • a wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention.
  • Useful expression vectors may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences.
  • Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., E.
  • coli plasmids col El, pCRl, pBR322, pMal-C2, pET, pGEX (Smith et al, 1988, Gene 67:31-40), pMB9 and their derivatives, plasmids such as RP4; phage DNAS, e.g., the numerous derivatives of phage ⁇ , e.g., NM989, and other phage DNA, e.g., M 13 and filamentous single stranded phage DNA; yeast plasmids such as the 2 ⁇ plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.
  • phage DNAS e.g., the numerous derivatives of phage ⁇ , e.g.
  • both non-fusion transfer vectors such as but not limited to pVL941 (BamHl cloning site; Summers), pVL1393 (BamHl, Smal, Xbal, EcoRl, Notl, XmaUl, Bgl ⁇ l, and Pstl cloning site; Invitrogen), pVL1392 (BgUI, Pstl, Notl, XmaUl, EcoRl, Xbal, Smal, and BamHl cloning site; Summers and Invitrogen), and pBlue5 ⁇ cIII (BamHl, BgUI, Pstl, Ncol, and Hindlll cloning site, with blue/white recombinant screening possible; Invitrogen), and fusion transfer vectors, such as but not limited to pAc700 (BamHl and Kpnl cloning site, in which the BamHl recognition
  • the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
  • Vectors are introduced into the desired host cells by methods known in the art, e.g. , transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, e.g. , Wu et al., 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263:14621-14624; Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990).
  • the component or components of a therapeutic composition of die invention may be introduced parenterally, transmucosally, e.g. , orally, nasally, or rectally, or transdermally.
  • administration is parenteral, e.g. , via intravenous injection, and also including, but is not limited to, intra-arteriole, intramuscular, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration.
  • the therapeutic compound can be delivered in a vesicle, in particular a liposome [see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss: New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.]. To reduce its systemic side effects, this may be a preferred method for introducing the peptides and antibodies of the present invention.
  • the therapeutic compound can be delivered in a controlled release system.
  • the peptides may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration.
  • a pump may be used [see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Swrgerv 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)].
  • polymeric materials can be used [see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Press: Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley: New York (1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J. Neurosurg. 71:105 (1989)].
  • a controlled release system can be placed in proximity of the therapeutic target, i.e., die brain, thus requiring only a fraction of die systemic dose [see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115- 138 (1984)].
  • recombinant cells that have been transformed with nucleic acids encoding eitiier the antigenic or inhibitory peptides of die present invention and express high levels of tiiese peptides can be transplanted in a subject in need of these peptides.
  • autologous cells transformed witii these peptides are transplanted to avoid rejection; alternatively, technology is available to shield non-autologous cells that produce soluble factors witiiin a polymer matrix that prevents immune recognition and rejection.
  • die therapeutic peptides of die present invention can be delivered by intravenous, intraarterial, intraperitoneal, intramuscular, or subcutaneous routes of administration.
  • ese peptides properly formulated can be administered by nasal or oral administration.
  • a constant supply of these peptides can be ensured by providing a therapeutically effective dose (i.e. , a dose effective to induce metabolic changes in a subject) at the necessary intervals, e.g., daily, every 12 hours, etc.
  • a therapeutically effective dose i.e. , a dose effective to induce metabolic changes in a subject
  • these parameters will depend on the severity of the disease condition being treated, otiier actions, the weight, age, and sex of the subject, and other criteria, which can be readily determined according to standard good medical practice by those of skill in the art.
  • a subject in whom administration of mese peptides is an effective therapeutic regiment is preferably a human, but can be any animal.
  • the methods and pharmaceutical compositions of the present invention are particularly suited to administration to any animal, particularly a mammal, and including, but by no means limited to, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., avian species, such as chickens, turkeys, songbirds, etc., i.e., for veterinary medical use.
  • Nasal Delivery Nasal delivery of the pharmaceutical compositions containing the inhibitory or antigenic peptides (or derivative thereof) is also contemplated. Nasal delivery allows the passage of the peptide to die blood stream directly after administering e therapeutic product to the nose, without the necessity for deposition of the product in d e lung.
  • Formulations for nasal delivery include tiiose with dextran or cyclodextran.
  • a useful device is a small, hard bottle to which a metered dose sprayer is attached.
  • me metered dose is delivered by drawing the solution of peptides into a chamber of defined volume, which chamber has an aperture dimensioned to aerosolize and aerosol formulation by forming a spray when a liquid in the chamber is compressed.
  • the chamber is compressed to administer the peptides.
  • me chamber is a piston arrangement.
  • Such devices are commercially available.
  • a plastic squeeze bottle with an aperture or opening dimensioned to aerosolize an aerosol formulation by forming a spray when squeezed.
  • the opening is usually found in me top of the bottle, and die top is generally tapered to partially fit in die nasal passages for efficient administration of the aerosol formulation.
  • the nasal inhaler will provide a metered amount of the aerosol formulation, for administration of a measured dose of d e drug.
  • microcosal penetration enhancer refers to a reagent that increases the rate or facility of transmucosal penetration of ketamine, such as but not limited to, a bile salt, fatty acid, surfactant or alcohol.
  • the permeation enhancer can be sodium cholate, sodium dodecyl sulphate, sodium deoxycholate, taurodeoxycholate, sodium glycocholate, dimethylsulfoxide or ethanol.
  • Suitable penetration enhancers also include glycyrrhetinic acid (U.S. Patent No.
  • polysorbate-80 preferably in combination with an non-ionic surfactant such as nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, or lauramide-DEA (European Patent EP 0 242 643 Bl by Stoltz).
  • an non-ionic surfactant such as nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, or lauramide-DEA (European Patent EP 0 242 643 Bl by Stoltz).
  • Transdermal patches are described in for example, U.S. Patent No. 5,407,713, issued April 18, 1995 to Rolando et al.; U.S. Patent No. 5,352,456, issued October 4, 1004 to Fallon et al.; U.S. Patent No. 5,332,213 issued August 9, 1994 to D'Angelo et al.; U.S. Patent No. 5,336,168, issued August 9, 1994 to Sibalis; U.S. Patent No. 5,290,561, issued March 1, 1994 to Farhadieh et al.; U.S. Patent No.
  • tiiat a transdermal route of administration may be enhanced by use of a dermal penetration enhancer, e.g., such as enhancers described in U.S. Patent No. 5,164,189 (supra), U.S. Patent No. 5,008,110 (supra), and U.S. Patent No. 4,879,119, issued November 7, 1989 to Aruga et al., the disclosure of each of which is incorporated herein by reference in its entirety.
  • the present invention may be better understood by reference to die following non-limiting Examples, which are provided as exemplary of the invention.
  • the anti-mucopeptide antibody was affinity purified in the following manner. Five ml of rabbit anti-mucopeptide antibody was first passed over a protein A sepharose column and the antibody fraction binding to the column was eluted in a 0.05 M sodium Acetate buffer pH 2.5. The volume of me eluant was adjusted back to d e original volume of the serum (5 ml) and the pH was adjusted to pH 7.2 witii 5N NAOH. 5 mg of streptococcal mucopeptide (dry weight) was then mixed witii 0.5 ml of anti-mucopeptide purified antibody and tiien rotated gently at 37 °C for 2-3 hours. The sample was stored overnight in the cold at 4°C.
  • the pellet was resuspended in 1 ml of 0.05 M sodium acetate buffer pH 2.5 and rotated gently at room temperature for 1 hour and men centrifuged as described above.
  • the pH of the supernatant was brought back to pH 7.2 by the addition of 5N NAOH and tiien tested witii an ELISA assay using a preparation of sonicated mucopeptide at a concentration of lug/well.
  • the ELISA titer was compared to me original non-absorbed antibody and the volume adjusted so mat the absorbed antibody has the same titer as the original non-absorbed anti-mucopeptide antibody.
  • the biological activity of the affinity purified antibody was then tested using human mononuclear cell preparations as described above. Serial dilutions of die affinity purified anti-mucopeptide antibody was then added to the wells followed by die addition of different concentrations of LPS and streptococcal cell wall mucopeptide preparations starting at a concentration of 100 ⁇ g/ml. Control samples included cells in which die antibody wasn't added. The cell suspension was incubated for 24 hrs at 37° C in a C0 2 incubator and tiien following the subsequent centrifugation, the supernatants were harvested and tested for TNF alpha production.
  • coli in low melting point LB agar which is men poured on top of LB agar plates. After incubating die plates at 37 °C for a period of time, small clear plaques in a lawn of E. coli will form which represents active phage growth and lysis of the E. coli.
  • a representative of these phages can be absorbed to nylon filters by placing dry filters onto the agar plates. The filters can be marked for orientation, removed, and placed in washing solutions to block any remaining absorbent sites. The filters can tiien be placed in a solution containing radioactive mucopeptide complex. After a specified incubation period, the filters can be thoroughly washed and developed for autoradiography.
  • Plagues containing the phage tiiat bind to the mucopeptide complex can be identified. These phages can be further cloned and tiien retested for their ability to bind to die mucopeptide complex as before. Once the phages have been purified, die binding sequence contained within the phage can be determined by standard DNA sequencing techniques. Once d e DNA sequence is known, synthetic peptides can be generated which represents tiiese sequences. These peptides can be tested for their ability to: (1) bind die mucopeptide complex, (2) bind to lipid A, and (3) inhibit the anti-mucopeptide antibodies. A single peptide witii strong positive results indicates a single dominant binding peptide.
  • Isolation of multiple peptides indicates tiiat the peptides have a common sequence, e.g. the phage library has generated d e exact same peptide more than once, or several difference peptides have a similar reactivity.
  • the peptide(s) shown positive by ELISA can be synthesized and assayed to test wheti er it (tiiey) can block the anti-mucopeptide effect on TNF induction by eitiier LPS or mucopeptide.
  • the effective peptide(s) can be syntiiesized in large quantities for use in animal models of shock and eventually in humans to prevent septic shock. It should be emphasized tiiat synthetic peptide production is relatively non-labor intensive, easily manufactured, quality controlled and tiius, large quantities of die desired product can be produced quite cheaply. Similar combinations of mass produced syntiietic peptides have recently been used in trials of a malaria vaccine with great success [Patarroyo, Vaccine 10:175-178 (1990)] and shown to be quite safe for use in humans.
  • the disease rheumatoid artiiritis is a disease of unknown etiology but presumed to be an autoimmune disease involving d e target organ, the joints. While many experimental models of artiiritis have been proposed (see Table 1), the streptococcal induced model is preferred for the following reasons. First, it is a single dose of a sonicated cell wall preparation which, unlike die otiier models, induces artiiritis which then waxes and wanes for over half the life of the animal. Secondly, die end result bears a striking resemblance to the human disease.
  • TNF plays an important role in disease induction and in an experimental model die disease can be blocked by injecting soluble TNF receptor molecules just after initiation of die disease.
  • ND indicates tiiat it has not been determined.
  • the inciting agent is primarily the streptococcal mucopeptide-polysaccharide complex
  • the approach to the model proceeds by two routes of investigation.
  • the first approach induces die experimental arthritis in rats.
  • animals are injected witii d e anti-mucopeptide antibody.
  • d e anti-mucopeptide antibody protects against disease induction.
  • the antibody can confer passive protection, the peptides described above can prevent the onset of die induced artiiritis when injected concurrently witii d e mucopeptide complex by I.V. or I.P.
  • tiiat protection can be passively transferred to a naive animal by antibodies, either by injecting the available anti-mucopeptide antibodies or tiiose antibodies elicited after injecting enzymatically derived fragments of the mucopeptide complex.
  • d ese antibodies can be used to identify peptide mimitopes of die mucopeptide fragments which will elicit a similar protective antibody response.
  • the protective antibodies can be used to identify peptides which mimic the structure of the fragments of the mucopeptide complex.
  • peptides have die following characteristics: (1) they react with the anti- mucopeptide antibodies, (2) tiiey do not bind to the mucopeptide complex, and (3) tiiey do not elicit a protective antibody response in animals against mucopeptide complex induced arthritic disease.
  • a similar strategy has been successfully used to find peptides that mimic the structure of Group C polysaccharide capsular antigens of Neisseria mengitidis [Westerink and Giardina, Microb.Patiiog. 12:19-26 (1992)]. These peptides can be used to induce a protective antibody response to experimental arthritis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rehabilitation Therapy (AREA)

Abstract

Cette invention concerne l'utilisation d'anticorps dirigés contre le mucopeptide du groupe A pour le traitement du choc septique et de la polyarthrite rhumatoïde, ainsi que l'identification de peptides spécifiques pouvant être utilisés dans ces traitements. Cette invention porte sur des procédés d'utilisation des anticorps dirigés contre le mucopeptide du groupe A; dans lesquels on utilise comme moyen d'identification des peptides spécifiques, sur les peptides spécifiques eux-mêmes et sur des procédés d'utilisation desdits peptides. Dans certaines formes de réalisation, les peptides spécifiques servent de mimétiques pour ces anticorps. Ces peptides peuvent être administrés à un sujet animal pour le blocage de l'action microbienne qui amorce la polyarthrite rhumatoïde par l'intermédiaire du facteur de nécrotumorale. On peut également utiliser les peptides spécifiques de cette invention pour immuniser des individus sujets à la polyarthrite rhumatoïde pour empêcher la progression des maladies. Dans d'autres formes de réalisation, les peptides servent de partenaires de liaisons pour ces anticoprs.
EP98930343A 1997-06-18 1998-06-17 Procedes d'identification d'anticorps et de peptides utiles dans le traitement du choc septique et de l'arthrite experimentale; utilisation de ces derniers Withdrawn EP1001805A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US87798897A 1997-06-18 1997-06-18
US5008797P 1997-06-18 1997-06-18
US50087P 1997-06-18
US877988 1997-06-18
US9783898A 1998-06-16 1998-06-16
US97838 1998-06-16
PCT/US1998/012647 WO1998057657A1 (fr) 1997-06-18 1998-06-17 Procedes d'identification d'anticorps et de peptides utiles dans le traitement du choc septique et de l'arthrite experimentale; utilisation de ces derniers

Publications (1)

Publication Number Publication Date
EP1001805A1 true EP1001805A1 (fr) 2000-05-24

Family

ID=27367667

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98930343A Withdrawn EP1001805A1 (fr) 1997-06-18 1998-06-17 Procedes d'identification d'anticorps et de peptides utiles dans le traitement du choc septique et de l'arthrite experimentale; utilisation de ces derniers

Country Status (5)

Country Link
EP (1) EP1001805A1 (fr)
JP (1) JP2002516634A (fr)
AU (1) AU730308B2 (fr)
CA (1) CA2295440A1 (fr)
WO (1) WO1998057657A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075119A (en) 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
CA1341375C (fr) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions pour le traitement et la prevention d'infections dues a des bacteries gram negatif, ainsi que leurs methodes d'utilisation
WO1991007986A1 (fr) * 1989-12-04 1991-06-13 Schering Corporation Methode de traitement de choc septique
AU1570792A (en) * 1991-03-15 1992-10-21 Univax Biologics Incorporated Lipid a analog/immunogenic carrier conjugates, the use thereof as vaccines and polyvalent hyperimmune gammaglobulins
NZ271893A (en) * 1993-08-23 1997-11-24 Immunex Corp Inhibitors of tnf-alpha secretion
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9857657A1 *

Also Published As

Publication number Publication date
AU7975398A (en) 1999-01-04
WO1998057657A1 (fr) 1998-12-23
AU730308B2 (en) 2001-03-01
JP2002516634A (ja) 2002-06-04
CA2295440A1 (fr) 1998-12-23

Similar Documents

Publication Publication Date Title
US5969102A (en) Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20030216544A1 (en) Methods and reagents for diagnosis of autoantibodies
US6231869B1 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
KR19990044347A (ko) 결핵의 면역치료 및 진단을 위한 화합물 및 방법
US20120156700A1 (en) Detection and quantitation of urine gelsolin
US6190659B1 (en) Bacterial plasmin binding protein and methods of use thereof
WO1994020614A1 (fr) Proteine et peptides allergenes obtenus a partir d'acariens detriticoles et leurs utilisations
WO2000000615A2 (fr) COMPOSES ET PROCEDES SERVANT A DIAGNOSTIQUER ET A TRAITER L'INFECTION PAR $i(EHRLICHIA)
US7169393B2 (en) Antigenic peptide fragments of VapA protein, and uses thereof
US6340463B1 (en) Identification of antigenic peptide sequences
EP0871734B1 (fr) Fragments polypeptidiques capables de concurrencer l'antigene i/ii de streptococcus mutans
CA2049921C (fr) Proteines allergenes de l'herbe a poux et leur utilisation
JP3990730B2 (ja) マラセチア由来の抗原性蛋白質
AU730308B2 (en) Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
AU4102893A (en) Methods and reagents for diagnosis of autoantibodies
JP2003501013A (ja) ローソニア由来の遺伝子及び関連ＳｏｄＣポリペプチド、ぺプチド及びタンパク質並びにそれらの使用
KR20060129229A (ko) 표면에 위치한 빈창자캄필로박터 폴리펩티드
JP2003521881A (ja) ローソニア由来の遺伝子及び関連ＯｍｐＨポリペプチド、ぺプチド及びタンパク質並びにそれらの使用
JP2003516113A (ja) ローソニア由来の遺伝子及び関連ＦｌｇＥポリペプチド、ぺプチド及びタンパク質並びにそれらの使用
CA2247072A1 (fr) Proteines d'origine bacterienne de fixation sur l'elastine, sequences d'acide nucleique codant ladite proteine et procedes diagnostiques et therapeutiques d'utilisation de cette proteine
AU2004224903A1 (en) Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses
US7153947B2 (en) Ixodes salivary anticomplement protein
JP2007534311A (ja) Ｂｒａｃｈｙｓｐｉｒａｐｉｌｏｓｉｃｏｌｉ７２ｋＤａ外膜タンパク質及び診断及び治療のためのその使用
MXPA02001231A (es) Metodos y composiciones para detectar taenia solium larval.
US6342218B1 (en) Method for treatment of SLE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030102

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1028734

Country of ref document: HK